Delighted to have supported Oxford Vacmedix to secure non-dilutive funding from @innovateuk for clinical development of their lead innovative #CancerVaccine https://t.co/nnjrQyo6fd
We're delighted to have our CEO, Oliver Kemp, featured prominently in today's @Telegraph. Our work, and the work of others, has created a host of promising new treatments which offer fresh hope even for advanced disease.
https://t.co/OfewzBX56j